NOX-E36

DRUG4 trials

Sponsors

TME Pharma AG

Conditions

AlbuminuriaChronic Inflammatory DiseasesRenal ImpairmentSystemic Lupus ErythematosusType 2 Diabetes Mellitus

Phase 1

NOX-E36 First-in-Human (FIH) Study

CompletedNCT00976729

TME Pharma AGChronic Inflammatory Diseases, Systemic Lupus Erythematosus, Type 2 Diabetes Mellitus

Start: 2009-05-31End: 2009-12-31Updated: 2013-02-13

NOX-E36 Multiple Ascending Dose Study in Healthy Volunteers and Patients With Type 2 Diabetes Mellitus

CompletedNCT01085292

TME Pharma AGType 2 Diabetes Mellitus

Start: 2010-07-31End: 2012-02-29Updated: 2013-02-13

A Phase I Clinical Trial to Evaluate the Effect of Renal Impairment on Pharmacokinetics of NOX-E36

CompletedNCT01372124

TME Pharma AGRenal Impairment

Start: 2011-06-30End: 2012-10-31Updated: 2012-10-19

Phase 2

NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria

CompletedNCT01547897

TME Pharma AGAlbuminuria, Type 2 Diabetes Mellitus

Start: 2012-03-31End: 2013-12-31Updated: 2014-02-24